Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
- Conditions
- Immunodeficiency
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 400
- Registration Number
- NCT04408950
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 1033
- Registration Number
- NCT04401579
- Locations
- 🇺🇸
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States
🇺🇸University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
- Conditions
- Coronavirus Disease 2019
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 625
- Registration Number
- NCT04401436
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸MedStar Health Research Institute: Washington Hospital Medical Center, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
- Conditions
- COVID-19
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Walter Reed National Medical Center, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
COVID-19 and Anti-CD14 Treatment Trial
- Conditions
- Coronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2023-06-26
- Target Recruit Count
- 49
- Registration Number
- NCT04391309
- Locations
- 🇺🇸
Sarasota Memorial Health Care System, Sarasota, Florida, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
Surveillance of Individuals Following SARS-CoV-2 Infection
- Conditions
- COVID-19
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-11-01
- Target Recruit Count
- 18
- Registration Number
- NCT04383444
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Immunophenotyping Assessment in a COVID-19 Cohort
- Conditions
- Coronavirus Disease 2019 (COVID-19)SARS-CoV-2
- Interventions
- Procedure: Biological sample collection
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2022-05-19
- Target Recruit Count
- 1227
- Registration Number
- NCT04378777
- Locations
- 🇺🇸
University of Arizona (UA) College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center, Tucson, Arizona, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States
COVID-19: Human Epidemiology and Response to SARS-CoV-2
- Conditions
- SARS-CoV-2Coronavirus Disease 2019 (COVID-19)
- Interventions
- Procedure: Collection of Biological SamplesProcedure: Symptom and Exposure Surveys
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 5599
- Registration Number
- NCT04375761
- Locations
- 🇺🇸
Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
- Conditions
- Severe Combined Immune Deficiency (SCID)
- Interventions
- Drug: SirolimusDrug: BusulfanDrug: Horse -Anti-thymocyteDrug: G-CSFRadiation: Total Body Irradiation (TBI)
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-01-10
- Target Recruit Count
- 30
- Registration Number
- NCT04370795
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
- Conditions
- COVID-19SARS-CoV 2
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2021-11-16
- Target Recruit Count
- 20
- Registration Number
- NCT04358068
- Locations
- 🇺🇸
Harbor-UCLA CRS, Torrance, California, United States
🇺🇸Greensboro CRS, Greensboro, North Carolina, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States